Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Gilbert

Showing results (411-420 of 453) with videos related to

Pageof 46
Sort By:
Eclinicalmedicine|November 17, 2022
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyElizabeth Vera, Alexa Christ, Ewa Grajkowska, et al.
Genes & Development|April 8, 2024
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotypeNicholas Nuechterlein, Allison Shelbourn, Frank Szulzewsky, et al.
Neuro-Oncology|September 23, 2021
Impact of the methylation classifier and ancillary methods on CNS tumor diagnosticsZhichao Wu, Zied Abdullaev, Drew Pratt, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Neuro-Oncology Advances|August 2, 2021
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessmentKarine A Al Feghali, James W Randall, Diane D Liu, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Neuro-Oncology Practice|July 19, 2021
Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History StudyJames L Rogers, Elizabeth Vera, Alvina Acquaye, et al.
Pageof 46

Showing results (411-420 of 453) with videos related to

Sort By:
Pageof 46
Eclinicalmedicine|November 17, 2022
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyElizabeth Vera, Alexa Christ, Ewa Grajkowska, et al.
Genes & Development|April 8, 2024
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotypeNicholas Nuechterlein, Allison Shelbourn, Frank Szulzewsky, et al.
Neuro-Oncology|September 23, 2021
Impact of the methylation classifier and ancillary methods on CNS tumor diagnosticsZhichao Wu, Zied Abdullaev, Drew Pratt, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Neuro-Oncology Advances|August 2, 2021
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessmentKarine A Al Feghali, James W Randall, Diane D Liu, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Neuro-Oncology Practice|July 19, 2021
Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History StudyJames L Rogers, Elizabeth Vera, Alvina Acquaye, et al.
Pageof 46